These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 10774635)

  • 1. Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients.
    Eap CB; Bender S; Gastpar M; Fischer W; Haarmann C; Powell K; Jonzier-Perey M; Cochard N; Baumann P
    Ther Drug Monit; 2000 Apr; 22(2):209-14. PubMed ID: 10774635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic drug interaction potential of risperidone with cytochrome p450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test.
    Eap CB; Bondolfi G; Zullino D; Bryois C; Fuciec M; Savary L; Jonzier-Perey M; Baumann P
    Ther Drug Monit; 2001 Jun; 23(3):228-31. PubMed ID: 11360030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients.
    Koyama E; Tanaka T; Chiba K; Kawakatsu S; Morinobu S; Totsuka S; Ishizaki T
    J Clin Psychopharmacol; 1996 Aug; 16(4):286-93. PubMed ID: 8835703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences.
    Tamminga WJ; Wemer J; Oosterhuis B; Weiling J; Wilffert B; de Leij LF; de Zeeuw RA; Jonkman JH
    Eur J Clin Pharmacol; 1999 May; 55(3):177-84. PubMed ID: 10379632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A.
    von Moltke LL; Greenblatt DJ; Grassi JM; Granda BW; Venkatakrishnan K; Schmider J; Harmatz JS; Shader RI
    J Pharm Pharmacol; 1998 Sep; 50(9):997-1004. PubMed ID: 9811160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groups.
    Britzi M; Bialer M; Arcavi L; Shachbari A; Kapitulnik T; Soback S
    Ther Drug Monit; 2000 Oct; 22(5):510-6. PubMed ID: 11034254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes.
    Rochat B; Amey M; Gillet M; Meyer UA; Baumann P
    Pharmacogenetics; 1997 Feb; 7(1):1-10. PubMed ID: 9110356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics.
    Kirchheiner J; Müller G; Meineke I; Wernecke KD; Roots I; Brockmöller J
    J Clin Psychopharmacol; 2003 Oct; 23(5):459-66. PubMed ID: 14520122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin.
    Eap CB; Guentert TW; Schãublin-Loidl M; Stabl M; Koeb L; Powell K; Baumann P
    Clin Pharmacol Ther; 1996 Mar; 59(3):322-31. PubMed ID: 8653995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers.
    Hägg S; Spigset O; Dahlqvist R
    Br J Clin Pharmacol; 2001 Feb; 51(2):169-73. PubMed ID: 11259990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics of ketobemidone are not affected by CYP2D6 or CYP2C19 phenotype.
    Al-Shurbaji A; Säwe J
    Eur J Clin Pharmacol; 2002 Feb; 57(12):877-81. PubMed ID: 11936707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population.
    Marandi T; Dahl ML; Kiivet RA; Rägo L; Sjöqvist F
    Pharmacol Toxicol; 1996 May; 78(5):303-7. PubMed ID: 8737964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of honey on CYP3A4, CYP2D6 and CYP2C19 enzyme activity in healthy human volunteers.
    Tushar T; Vinod T; Rajan S; Shashindran C; Adithan C
    Basic Clin Pharmacol Toxicol; 2007 Apr; 100(4):269-72. PubMed ID: 17371531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline.
    Baumann P; Meyer JW; Amey M; Baettig D; Bryois C; Jonzier-Perey M; Koeb L; Monney C; Woggon B
    Ther Drug Monit; 1992 Feb; 14(1):1-8. PubMed ID: 1546384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination.
    Tennezé L; Verstuyft C; Becquemont L; Poirier JM; Wilkinson GR; Funck-Brentano C
    Clin Pharmacol Ther; 1999 Dec; 66(6):582-8. PubMed ID: 10613613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma Concentrations and Cardiovascular Effects of Citalopram Enantiomers After Oral Versus Infusion Citalopram Therapy in Dextromethorphan-Mephenytoin-Phenotyped Patients With Major Depression.
    Baumann P; Bertschy G; Ramseier F; Nil R
    Ther Drug Monit; 2021 Jun; 43(3):436-442. PubMed ID: 33060488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia.
    Marandi T; Dahl ML; Rägo L; Kiivet R; Sjöqvist F
    Eur J Clin Pharmacol; 1997; 53(3-4):257-60. PubMed ID: 9476041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imipramine demethylation in vivo: impact of CYP1A2, CYP2C19, and CYP3A4.
    Madsen H; Rasmussen BB; Brøsen K
    Clin Pharmacol Ther; 1997 Mar; 61(3):319-24. PubMed ID: 9084457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reproducibility over time of mephenytoin and debrisoquine hydroxylation phenotypes.
    Llerena A; Valdivielso MJ; Benítez J; Bertilsson L
    Pharmacol Toxicol; 1993 Jul; 73(1):46-8. PubMed ID: 8234192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans.
    Kuhn UD; Kirsch M; Merkel U; Eberhardt AM; Wenda B; Maurer I; Härtter S; Hiemke C; Volz HP; Balogh A
    Int J Clin Pharmacol Ther; 2007 Jan; 45(1):36-46. PubMed ID: 17256449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.